U.S company, FlowAid Medical Technologies Corp., has received CE mark approval for its FA100 SCCD Sequential Contraction Compression Device.
Sequential compression is the current standard of care for treating many forms of circulatory disorders in the lower extremities. Until now, this was achieved with external pressure to the leg, but the FlowAid system works by delivering a number of electrically stimulated controlled contractions. The primary mechanism of the FlowAid FA100 SCCD is to compress the veins in the lower leg by using specifically controlled wave of peristaltic contractions, distal to proximal, causing an increase in Venous Outflow from the limb. This is useful in the treatment of Chronic Venous Insufficiency, Lymphedema, and the complications of these diseases. Keeping a constant flow will also prevent Deep Vein Thrombosis (DVT) from occurring. Secondarily, by increasing Venous Outflow, the FA100 SCCD also increases Arterial Inflow. This is useful for the treatment of Peripheral Arterial Disease (PAD), Arterial Insufficiency and the complications that may develop from these conditions. The FA100 SCCD has been useful in treating Microischemic Neuropathy by hyperperfusing the limb.
FlowAid says its FA100 SCCD was designed with the patient in mind, being easy to use, allowing complete mobility and operating without external pressure to the leg.
Source: Business Wire